| Identification | Back Directory | [Name]
SKF 83959 HYDROBROMIDE | [CAS]
80751-85-5 | [Synonyms]
SKF 83959 hydrobromi
SKF 83959 HYDROBROMIDE
SKF83959, 10 mM in DMSO
N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol
6-Chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol
1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-
6-CHLORO-7,8-DIHYDROXY-3-METHYL-1-(3-METHYLPHENYL)-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE
6-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-1-(3-METHYLPHENYL)-1H-3-BENZAZEPINE-7,8-DIOL HYDROBROMIDE
6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide | [Molecular Formula]
C18H20ClNO2 | [MDL Number]
MFCD03792727 | [MOL File]
80751-85-5.mol | [Molecular Weight]
317.81 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at RT | [solubility ]
DMSO: 26 mg/mL, soluble | [form ]
solid | [color ]
white | [InChI]
1S/C18H20ClNO2.BrH/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19;/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3;1H | [InChIKey]
FHYWNBUFNGHNCP-UHFFFAOYSA-N | [SMILES]
Br[H].CN1CCc2c(Cl)c(O)c(O)cc2C(C1)c3cccc(C)c3 |
| Hazard Information | Back Directory | [Uses]
SKF-83959 was used in dopamine signaling studies on eye blinking in monkeys and on phosphorylation of CaMKIIα in mice. | [Definition]
ChEBI: A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a 3-methylphenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 6 and two hydroxy substituents at positions 7 and 8. Dopamine D1-like receptor p
rtial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine. | [Biological Activity]
Dopamine D 1 -like receptor partial agonist (K i values are 1.18, 7.56, 920 and 399 nM for rat D 1 , D 5 , D 2 and D 3 receptors respectively). May act as an antagonist in vivo , producing antiparkinsonian effects and antagonizing the behavioral effects of cocaine. | [in vivo]
SKF83959 (0.5 and 1 mg/kg; i.p.; 1 hour) reverses the scopolamine-induced cognitive impairments in the passive avoidance task and Y-Maze test[1].
SKF83959 (1 mg/kg; i.p.; 30 minutes) induced memory enhancing effects are prevented by brain-derived neurotrophic factor system blockade[1].
SKF83959 has anti-amnesic activities and restores the scopolamine-decreased BDNF signaling pathway in the hippocampus in mice[1]. | Animal Model: | Male ICR male mice (8 weeks)[1] | | Dosage: | 0.5 and 1 mg/kg | | Administration: | I.p.; 1 hour | | Result: | Reversed the scopolamine-induced cognitive impairments in the passive avoidance task and Y-Maze test.
|
| Animal Model: | Male ICR male mice (8 weeks)[1] | | Dosage: | 1 mg/kg | | Administration: | I.p.; 30 minutes | | Result: | The memory enhancing effects were prevented by BDNF system blockade.
|
| [IC 50]
D1 Receptor: 1.18 nM (Ki); Sigma 1 Receptor; D5 Receptor: 7.56 nM (Ki); D2 Receptor: 920 nM (Ki); D3 Receptor: 399 nM (Ki) |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
SIGMA-RBI
|
| Tel: |
800 736 3690 (Orders) |
| Website: |
www.sigma-aldrich.com |
|